Tags : Skyrizi

AbbVie Reports Results of Skyrizi (risankizumab) in P-III Induction Studies

Tuba Khan January 11, 2021

Shots: The P-III ADVANCE & MOTIVATE studies involves assessing of Risankizumab (600/1200mg) vs PBO in adult patients with mod. to sev. CD who had an inadequate response/ were intolerant to conventional and/or biologic therapy & patients who had responded inadequately or were intolerant to biologic therapy respectively Results: @12wks. clinical remission as per CDAI (45%/42% […]Read More

Biotech Clinical Trials

AbbVie Reports Results of Skyrizi (Risankizumab) in P-III Studies for

Tuba Khan January 6, 2021

Shots: The two P-III studies KEEPsAKE-1 & -2 involves assessing Skyrizi (150mg) vs PBO followed by risankizumab (150mg, @24wks.) in patients with active PsA who had an inadequate response or intolerant to at least one biologic therapy and/or non-biologic DMARDs respectively Results: ACR20 (57% & 51% vs 34% & 27%); ACR50 (33% & 26% vs […]Read More

Clinical Trials

AbbVie Reports Results of SKYRIZI (risankizumab) in P-III LIMMitless Study

Tuba Khan October 30, 2020

Shots: The P-III LIMMitless study is designed to evaluate the long-term safety & efficacy assessing risankizumab (150 mg q12wks.) continuous risankizumab with a loading dose in adults with moderate to severe plaque psoriasis. The analysis includes integrated data from five P-II & III studies (ultIMMa-1, ultIMMa-2, SustaIMM, IMMvent and NCT03255382) and the LIMMitless study Results: […]Read More

Pharma

Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III

Tuba Khan June 11, 2019

Shots: The P-III IMMhance study results involves assessing of Skyrizi (SC, 150mg) vs PBO in patients in a ratio (4:1) for moderate to severe plaque psoriasis for 2yrs. The P-III IMMhance study results: @94wk. complete skin clearance; sPGA 0 (73%); PASI 100 (72%); @16wks. met 1EPs of the first phase of the study; @52wks. met […]Read More

Regulatory

AbbVie’s Skyrizi (risankizumab) Receives European Commission’s Approval for Moderate to

Tuba Khan May 1, 2019

Shots: The EC approval is based on four P-III ultIMMa-1, ultIMMa-2, IMMvent & IMMhance assessing Skyrizi (risankizumab) vs PBO, adalimumab, ustekinumab in 2000+ adult patients with moderate to severe plaque psoriasis The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%, 84% & 75%); Skyrizi vs adalimumab, PASI 90 (72% vs 47%); switched patients […]Read More

Regulatory

AbbVie’s Skyrizi (risankizumab) Receives Health Canada’s Approval for Moderate to

Tuba Khan April 19, 2019

Shots: The Health Canada approval is based on four P-III studies ultIMMa-1, ultIMMa-2, IMMvent and IMMhance assessing Skyrizi (risankizumab) vs PBO, adalimumab, ustekinumab in >2000 adult patients with moderate to severe plaque psoriasis The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%, 84% & 75%); Skyrizi vs adalimumab, PASI 90 (72% vs 47%); […]Read More

Pharma

AbbVie’s Skyrizi (risankizumab) Receives Japanese Ministry of Health, Labour and

Vartika Singh March 26, 2019

Shots: The approval is based on P-II & P-III sustaIMM, ultIMMa-1 and IMMspire study results assessing Skyrizi in Japanese patients with plaque psoriasis, generalized pustular psoriasis and erythrodermic psoriasis & active psoriatic arthritis The study resulted in safe and effective results and has capabilities to improve the signs of these chronic immune-mediated diseases Skyrizi (risankizumab) […]Read More

Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases

Boehringer Ingelheim Collaborates with Cure Genetics to Develop Next-Generation Liver-Targeted Gene Therapy

Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia

Henlius’ HLX15 (biosimilar, daratumumab) Receives IND Approval for Multiple Myeloma in China

Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19

The US Government to Purchase Additional Doses of Regeneron’s Casirivimab and Imdevimab to Combat COVID-19

Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma

Genmab’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) Receives the US FDA’s Approval for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

Nanobiotix Presents Results of NBTXR3 (PEP503) in P-Ib/II Study for Rectal Cancer at ASCO-GI 2021

Tags : Skyrizi

AbbVie Reports Results of Skyrizi (risankizumab) in P-III Induction Studies

AbbVie Reports Results of Skyrizi (Risankizumab) in P-III Studies for

AbbVie Reports Results of SKYRIZI (risankizumab) in P-III LIMMitless Study

Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III

AbbVie’s Skyrizi (risankizumab) Receives European Commission’s Approval for Moderate to

AbbVie’s Skyrizi (risankizumab) Receives Health Canada’s Approval for Moderate to

AbbVie’s Skyrizi (risankizumab) Receives Japanese Ministry of Health, Labour and

Latest Posts

ViewPoints Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App

Philips to Acquire Capsule Technologies for ~$635M

Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia

Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

Tags : Skyrizi

Latest Posts

Categories

Related Topics